BC PharmaCare coverage is changing for people who take Remicade® (infliximab) for the treatment of Crohn's disease or ulcerative colitis.
 
In light of this, CDHF wants to understand the recent experiences of people living in Canada who have switched/transitioned from Remicade® (infliximab) to the biosimilar versions of infliximab: Inflectra® and Renflexis™.

If you haven't been asked to switch/transition yet, please note that we will keep this survey open for a few months so you can come back to it and complete it. 

This survey is only for people living in the Canada, aged 18+ who have switched/transitioned from the biologic Remicade® to the biosimilar Inflectra® or Renflexis™.
Online Surveys  by